美拉基因治疗
MGTX
9.28
-0.61
-6.17%
美拉基因治疗
US · MGTX
#3220 按市值排名
上市于 2018
9.28
-0.61
-6.17%
实时 - 追踪5344个代码 - 心跳于380秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了3家。
- 机构持股总比例下降了2.1个百分点。
机构持股
- 机构持股比例
- 83.93% -2.09pp
- 机构数量
- 194 +3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund29.94%
VC/PE Fund20.37%
Mutual Fund17.12%
Public Company15.03%
Individual/Insider3.55%
Insurance Company0.80%
Private Company0.41%
Government Pension Fund0.26%
Other12.52%
主要股东 截至 2026-06-30
Sanofi
12.70% · 12.20M 股
Perceptive Advisors LLC
11.23% · 10.79M 股
Rubric Capital Management LP
9.47% · 9.10M 股
Johnson & Johnson Innovation - JJDC, Inc.
6.91% · 6.64M 股
BlackRock
4.95% · 4.76M 股
Adage Capital Management, L.P.
4.58% · 4.40M 股
Opaleye Management Inc.
3.70% · 3.55M 股
Millennium Management LLC
3.09% · 2.97M 股
683 Capital Management, LLC
2.39% · 2.30M 股
Woodline Partners LP
1.56% · 1.50M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 28次买入 · 21次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Perceptive Advisors LLC | -- | 11.23% |
| Alexandria Forbes | Chief Executive Officer | 1.38% |
| Richard Giroux | Chief Financial Officer | 1.04% |
| Stuart Naylor | Chief Development Officer | 0.67% |
| Keith Harris | Independent Chairperson | 0.21% |
| Robert Zeldin | Chief Medical Officer | 0.18% |
| Robert Wollin | General Counsel | 0.06% |
| Neil Mendoza | Independent Director | 0.01% |
| Nicole Seligman | Independent Director | 0.01% |
| Jiuyun Yu | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-05 | Stuart Naylor | Chief Development Officer | Intent to Sell (Form 144) | -27,659 | $10.64 |
| 2026-09-22 | Alan Sebulsky | Director | Other Derivative Acquisition | +100,000 | -- |
| 2026-09-22 | Apothecary Capital LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-17 | Alexandria Forbes | Chief Executive Officer | Automatic Disposition | -62,000 | $13.86 |
| 2026-07-20 | Richard Giroux | Chief Financial Officer | Automatic Disposition | -56,000 | $12.51 |
| 2026-07-06 | Stuart Naylor | Chief Development Officer | Automatic Disposition | -27,659 | $13.86–14.90 |
| 2026-06-24 | Alexandria Forbes | Chief Executive Officer | Other Derivative Acquisition | +980,000 | -- |
| 2026-06-24 | Richard Giroux | Chief Financial Officer | Other Derivative Acquisition | +980,000 | -- |
| 2026-06-24 | Stuart Naylor | Chief Development Officer | Other Derivative Acquisition | +70,000 | -- |
| 2026-06-24 | Robert Zeldin | Chief Medical Officer | Other Derivative Acquisition | +100,000 | -- |
| 2026-06-24 | Robert Wollin | General Counsel | Other Derivative Acquisition | +100,000 | -- |
| 2026-06-10 | Jiuyun Yu | Independent Director | Other Derivative Acquisition | +60,000 | -- |
| 2026-06-10 | Thomas Shenk | Independent Director & Member of Scientific Advisory Board | Other Derivative Acquisition | +69,662 | -- |
| 2026-06-10 | Keith Harris | Independent Chairperson | Other Derivative Acquisition | +106,441 | -- |
| 2026-06-10 | Perceptive Advisors LLC | -- | Other Derivative Acquisition | +60,000 | -- |
| 2026-06-10 | Nicole Seligman | Independent Director | Other Derivative Acquisition | +60,000 | -- |
| 2026-06-10 | Neil Mendoza | Independent Director | Other Derivative Acquisition | +66,641 | -- |
| 2026-06-10 | Ellen Hukkelhoven | Independent Director | Other Derivative Acquisition | +60,000 | -- |
| 2026-06-09 | Keith Harris | Independent Chairperson | Derivative Exercise and Retained | +75,000 | -- |
| 2026-05-18 | Alexandria Forbes | Chief Executive Officer | Automatic Disposition | -62,000 | $9.17 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:13 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
美拉基因治疗 讨论区 0 条评论